Quality of life and pain management data adds to efficacy results of combining TTFields with gemcitabine and nab-paclitaxel as a potential new option of care

Study findings show that ctDNA is a stronger biomarker than carcinoembryonic antigen to select patients who may benefit from metastasis-directed therapy

Study indicates that PARP inhibition could extend treatment options for patients with biliary tract cancers

Randomised trials and real-world data propel the anti-EGFR rechallenge approach towards standard of care, but more solid evidence is needed

Despite greater attention being given to treatment effects on patient wellbeing, the high heterogeneity of methodologies still limits the usefulness of QoL assessment

Data from the TALENTACE trial add to growing evidence supporting the combination of immunotherapy plus anti-VEGF component with TACE

Encouraging data were presented for FGF19-positive tumours and those with worse hepatic function, performance status or advanced vascular invasion

Preliminary results revealed that the combination of claudin 18.2/4-1BB bispecific antibody with nivolumab and mFOLFOX was also well tolerated